Pages that link to "Q39784230"
Jump to navigation
Jump to search
The following pages link to Treatment of advanced leukemia in mice with mRNA engineered T cells (Q39784230):
Displaying 50 items.
- CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL) (Q26783433) (← links)
- Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond (Q26861563) (← links)
- Chimeric antigen receptor therapy for cancer (Q27013599) (← links)
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges (Q27025300) (← links)
- CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia (Q28081600) (← links)
- T-cell receptor gene therapy--ready to go viral? (Q28081611) (← links)
- Children's Oncology Group's 2013 blueprint for research: stem cell transplantation. (Q33783145) (← links)
- Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells (Q33833475) (← links)
- Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation (Q33874986) (← links)
- The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer (Q33993529) (← links)
- Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition (Q34047618) (← links)
- Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. (Q34270375) (← links)
- Genetically engineered T cells for the treatment of cancer (Q34645898) (← links)
- Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity (Q34765959) (← links)
- Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia. (Q35146288) (← links)
- Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice (Q36028047) (← links)
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia (Q36279306) (← links)
- Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells (Q36470354) (← links)
- CAR-T Cell Therapy for Lymphoma. (Q36519358) (← links)
- The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies (Q36547199) (← links)
- Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor (Q36557169) (← links)
- Enhanced function of redirected human T cells expressing linker for activation of T cells that is resistant to ubiquitylation (Q36562605) (← links)
- Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition (Q36720681) (← links)
- Transient Expression of an LEDGF/p75 Chimera Retargets Lentivector Integration and Functionally Rescues in a Model for X-CGD. (Q36738381) (← links)
- Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond (Q36845643) (← links)
- Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA. (Q36882726) (← links)
- Antibody-based therapeutics for the treatment of human B cell malignancies (Q36907540) (← links)
- pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences. (Q37238914) (← links)
- Design and development of therapies using chimeric antigen receptor-expressing T cells (Q37418289) (← links)
- Challenges of creating effective chimeric antigen receptors for cancer therapy (Q37436527) (← links)
- T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. (Q37466219) (← links)
- Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. (Q37599478) (← links)
- New development in CAR-T cell therapy (Q37658246) (← links)
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells (Q37697847) (← links)
- Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis (Q37706662) (← links)
- Driving CAR-based T-cell therapy to success (Q37715684) (← links)
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies (Q37723469) (← links)
- Targeted gene therapies: tools, applications, optimization (Q38005211) (← links)
- Autologous regulatory T cells for the treatment of type 1 diabetes (Q38030480) (← links)
- Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials (Q38035043) (← links)
- T cell-based gene therapy of cancer (Q38068003) (← links)
- Adoptive immunotherapy for cancer. (Q38170496) (← links)
- Adoptive immunotherapy for cancer or viruses (Q38178359) (← links)
- mRNA-based therapeutics--developing a new class of drugs (Q38252360) (← links)
- mRNA transcript therapy (Q38264088) (← links)
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies (Q38289029) (← links)
- Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells (Q38353123) (← links)
- Lentiviral vectors in cancer immunotherapy (Q38389312) (← links)
- Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors (Q38426341) (← links)
- Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy (Q38435415) (← links)